Searchable abstracts of presentations at key conferences in endocrinology

ea0014p142 | (1) | ECE2007

Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer

Pivonello Rosario , Ferolla Piero , Faggiano Antongiulio , Ferone Diego , Cerasola Enrica , Angeletti Gabriella , Santeusanio Fausto , Minuto Francesco , Lombardi Gaetano , Lamberts Steven WJ , Hofland Leo J , Colao Annamaria

Dopamine receptors was suggested to be expressed in medullary thyroid cancer (MTC). The aim of the current study was to evaluate the expression of D2 dopamine receptor in MTC and the effectiveness of the dopamine agonist cabergoline in patients with MTC. Five paraffin-embedded cases of MTC obtained after thyroidectomy were used to evaluate D2 receptor expression by immunohistochemistry. Fifteen patients (7 males, 8 females, 36–78 years) with post-sur...

ea0014p558 | (1) | ECE2007

Cabergoline treatment in Cushing’s disease: effect on hypertension, glucose intolerance and dyslipidemia.

Pivonello Rosario , Martino Maria Cristina De , Faggiano Antongiulio , Leo Monica De , Lombardi Gaetano , Hofland Leo J , Lamberts Steven WJ , Colao Annamaria

Cabergoline has been recently demonstrated to normalize cortisol secretion in more than one third of patients with Cushing’s disease (CD). The aim of this study was to evaluate short-term (3-months) and long-term (12-24 months) effects of cabergoline treatment on the main systemic complications of CD, including hypertension, glucose intolerance and dyslipidemia. Twenty patients with CD unsuccessfully treated by neurosurgery entered the study. Cabergoline was admistered at...

ea0013p186 | Diabetes, metabolism and cardiovascular | SFEBES2007

Mitochondrial genes related to energy homoeostasis are dysregulated in obesity and type 2 diabetes in human adipose tissue

McGee Kirsty C , Hardo Faddy J , Baker Adam R , Tripathi Gyanendra , Creely Steven J , da Silva Nancy F , Kumar Sudhesh , Clapham John C , McTernan Philip G

Mitochondrial dysfunction has been implicated in the pathogenesis of obesity and Type 2 Diabetes Mellitus (T2DM). Recent research has investigated the role of mitochondria in skeletal muscle and suggesting mitochondrial dysregulation may be linked to T2DM. To date few studies have focused on the role of human adipose tissue (AT) in energy homoeostasis. Therefore we investigated a number of mitochondrial genes including PPARγ co-activator1 (PGC1α, mitochondrial biogen...

ea0073aep488 | Pituitary and Neuroendocrinology | ECE2021

Pituitary surgery in northern ireland: A twenty year retrospective population based analysis

Loughrey Paul Benjamin , Craig Stephanie , Herron Brian , Cooke Stephen , Weir Philip , Bhattacharya Debarata , Sturdy Erin , Salto-Tellez Manuel , Parkes Eileen , McArt Darragh , Korbonits Marta , Hunter Steven , James Jacqueline

In Northern Ireland, the sole tertiary referral centre for pituitary disease which includes neurosurgery and endocrinology for ~1.9 million people, is based in the Royal Victoria Hospital, Belfast. A retrospective study has been commenced to examine clinical, biochemical, histopathological and radiological data for all patients operated on across an approximately 20 year period in Northern Ireland. Ethical approval was obtained from the Northern Ireland Biobank (study num...

ea0094p96 | Neuroendocrinology and Pituitary | SFEBES2023

A first report of pituitary Neuro-Endocrine-Tumour in a young patient with Coffin-Siris syndrome. Is there a link between the ARID1B c.6157dup gene and pituitary tumourigenesis?

Macfarlane James , Lin Nyan , Serban Laura , Sennik Devesh , Ping Jen Jian , Mes Steven , Dean Andrew , Koulouri Olympia , Donelly Neil , Mannion Richard , Gurnell Mark , Panteliou Eleftheria

A 19-year-old gentleman, with Coffin-Siris-Syndrome(CSS)(ARID1B:c.6157dup gene-mutation), was referred to our endocrinology clinic, with rapid weight-gain and recent onset of Type-2-Diabetes. He was of short stature, he had central-adiposity, facial plethora, proximal myopathy and gynaecomastia. Endocrine testing revealed ACTH:61ng/l, Cortisol:772nmol/l, Total-Testosterone:2.8nmol/l, FSH:6.3U/l, LH:2.2U/l, Prolactin:87mU/l, IGF-1:61ug/l, TSH:0.18mU/l, T4:10.3 pmol/l, HbA1C:84m...

ea0098c5 | Clinical – Chemo/SSA/Biologics | NANETS2023

A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial

Jimenez Camilo , Habra Mouhammed A. , Campbell Matthew T. , Tamsen Gina , Cruz-Goldberg Damaris , Long James , Bassett Roland , Dantzer Robert , Balderrama Vania , Varghese Jeena , Waguespack Steven , Lu Yang

Background: Metastatic pheochromocytomas and paragangliomas are orphan neuroendocrine tumors. 50% of these tumors are associated with germline mutations of the SDHB gene. SDHB related pheochromocytomas and paragangliomas and many apparently sporadic tumors exhibit abnormal angiogenesis. This trial assessed the efficacy and safety of Cabozantinib, a potent, antiangiogenic, tyrosine kinase inhibitor. Methods: The Natalie trial is a single arm phase 2 clini...

ea0098c31 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

Al-Ward Ruaa , Balderrama Brondan Vania , Sawani Sahar , Bassett Roland , Xu Guofan , Waguespack Steven G. , Varghese Jeena , Amir Habra Mouhammed , Lu Yang , Jimenez Camilo

Background: Metastatic pheochromocytomas and paragangliomas are rare neuroendocrine tumors with limited treatment options. We studied the efficacy and safety of off-label High-Specific-Activity I-131-meta-iodobenzylguanidine (HSA-I-131-MIBG) in routine clinical practice. Methods: This is a retrospective cohort study. The primary endpoint is objective response rate (ORR) as per RECIST v1.1. Secondary endpoints are blood pressure control, safety, overall a...

ea0085p83 | Pituitary and Growth 2 | BSPED2022

DNA haplotypes influencing the response to growth hormone therapy are disproportionately inherited from neanderthals

Murray Philip , Hussain Asad , Garner Terence , Stevens Adam

Background: Neanderthals split from an ancestral human population ~500,000 years ago and lived in Eurasia until 40,000 years ago. Early modern humans emerged in Africa ~350,000 years ago migrating into Eurasia 50,000 years ago. Interbreeding occurred between early modern humans and Neanderthals leading to the introduction of Neanderthal DNA into the early human population, a process termed introgression. In modern Eurasian populations around 2-4% of DNA is of Neanderthal origi...

ea0034p164 | Growth and development | SFEBES2014

Distinct gene expression is associated with epigenetic and growth-related network modules in relation to gender differences in the timing of the pubertal growth spurt

De Leonibus Chiara , Chatelain Pierre , Clayton Peter , Stevens Adam

Background: The return to active long bone growth in puberty is a distinctly human event1 and occurs ~2 years earlier in girls compared to boys. Evolutionarily conserved networks of genes are associated with the developmental phases of childhood in multiple tissues2, implying the existence of a genetic program that controls the pubertal return to growth.Objectives: To identify biological functions associated with gender and age-rela...

ea0081oc3.2 | Oral Communications 3: Thyroid 1 | ECE2022

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Durante Cosimo , Brose Marcia , Robinson Bruce , Sherman Steven I , Jarzab Barbara , Lin Chia-Chi , Vaisman Fernanda , Hoff Ana O , Hitre Erika , Bowles Daniel W , Sen Suvajit , Patel Purvi , Keam Bhumsuk , Capdevila Jaume

Background: At a preplanned interim analysis (median follow-up 6.2 months) of the double-blind, phase 3 COSMIC-311 trial (NCT03690388), cabozantinib significantly improved progression-free survival (PFS) vs placebo (HR 0.22, 96% CI 0.13-0.36; P<0.0001) in 187 patients with previously treated radioiodine-refractory DTC (Brose, Lancet Oncol; 2021). Patients must have received lenvatinib or sorafenib and progressed during or after 1-2 prior VEGFR inhibitors. We prese...